RU2010128543A - Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов - Google Patents
Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов Download PDFInfo
- Publication number
- RU2010128543A RU2010128543A RU2010128543/04A RU2010128543A RU2010128543A RU 2010128543 A RU2010128543 A RU 2010128543A RU 2010128543/04 A RU2010128543/04 A RU 2010128543/04A RU 2010128543 A RU2010128543 A RU 2010128543A RU 2010128543 A RU2010128543 A RU 2010128543A
- Authority
- RU
- Russia
- Prior art keywords
- trifluoromethyl
- alkyl
- pyrrolidin
- methyl
- carbonyl
- Prior art date
Links
- -1 CARBOXAMIDE COMPOUNDS Chemical class 0.000 title claims 13
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract 60
- 150000001875 compounds Chemical class 0.000 claims abstract 40
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 28
- 229910052736 halogen Inorganic materials 0.000 claims abstract 26
- 150000002367 halogens Chemical group 0.000 claims abstract 26
- 125000003118 aryl group Chemical group 0.000 claims abstract 24
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 23
- 239000001257 hydrogen Substances 0.000 claims abstract 22
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 21
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 9
- 125000001424 substituent group Chemical group 0.000 claims abstract 9
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims abstract 8
- 125000004475 heteroaralkyl group Chemical group 0.000 claims abstract 8
- 125000002947 alkylene group Chemical group 0.000 claims abstract 7
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract 4
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000004450 alkenylene group Chemical group 0.000 claims abstract 2
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims abstract 2
- 125000004419 alkynylene group Chemical group 0.000 claims abstract 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims abstract 2
- 125000000732 arylene group Chemical group 0.000 claims abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims abstract 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims abstract 2
- 125000005549 heteroarylene group Chemical group 0.000 claims abstract 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 239000011593 sulfur Substances 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- UOTRVDWAHQBYSJ-UHFFFAOYSA-N 3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbaldehyde Chemical compound C1CN(C=O)CC2=CC(C(F)(F)F)=CN=C21 UOTRVDWAHQBYSJ-UHFFFAOYSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- LYUCMMACNKQXBC-UHFFFAOYSA-N 5-[[3-(methoxymethyl)-3-[7-(trifluoromethyl)-3,4-dihydro-1h-isoquinoline-2-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=CC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)OC3=CC=2)CC1 LYUCMMACNKQXBC-UHFFFAOYSA-N 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 claims 1
- SSOYENULCYRPAJ-UHFFFAOYSA-N 1-methyl-6-[[3-(3-methylbutyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]quinolin-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(CCC(C)C)CN(CC=2C=C3C=CC(=O)N(C)C3=CC=2)CC1 SSOYENULCYRPAJ-UHFFFAOYSA-N 0.000 claims 1
- NPJCOYIDFDZMOG-UHFFFAOYSA-N 1-methyl-7-[[4-(2-methylpropyl)-4-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]piperidin-1-yl]methyl]quinolin-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(CC(C)C)CCN(CC=2C=C3N(C)C(=O)C=CC3=CC=2)CC1 NPJCOYIDFDZMOG-UHFFFAOYSA-N 0.000 claims 1
- CKLRTGAHPHXPHJ-UHFFFAOYSA-N 2-[1-[(3-methyl-2-oxo-1,3-benzoxazol-5-yl)methyl]-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-3-yl]acetonitrile Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C(CC#N)(C1)CCN1CC1=CC=C(OC(N2C)=O)C2=C1 CKLRTGAHPHXPHJ-UHFFFAOYSA-N 0.000 claims 1
- ALCYOSUIJKKPLE-UHFFFAOYSA-N 2-[3-(methoxymethyl)-1-[(3-methyl-2-oxo-1,3-benzoxazol-5-yl)methyl]pyrrolidine-3-carbonyl]-7-(trifluoromethyl)-3,4-dihydro-1h-isoquinoline-5-carbonitrile Chemical compound C1CC(C(=CC(=C2)C(F)(F)F)C#N)=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)OC3=CC=2)CC1 ALCYOSUIJKKPLE-UHFFFAOYSA-N 0.000 claims 1
- MCOGDABTARIBNK-UHFFFAOYSA-N 3-ethyl-6-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C(COC)(C1)CCN1CC1=CC=C2N(CC)C(=O)OC2=C1 MCOGDABTARIBNK-UHFFFAOYSA-N 0.000 claims 1
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical compound OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 claims 1
- PXLYWESPZIWCFD-UHFFFAOYSA-N 5-[1-[3-(cyclopropylmethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]ethyl]-1,3-dimethylbenzimidazol-2-one Chemical compound C=1C=C2N(C)C(=O)N(C)C2=CC=1C(C)N(C1)CCC1(C(=O)N1CC2=CC(=CN=C2CC1)C(F)(F)F)CC1CC1 PXLYWESPZIWCFD-UHFFFAOYSA-N 0.000 claims 1
- DLTOCWLUDPHWJE-UHFFFAOYSA-N 5-[1-[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]cyclopropyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1C(COC)(C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CCN1C1(C=2C=C3N(C)C(=O)OC3=CC=2)CC1 DLTOCWLUDPHWJE-UHFFFAOYSA-N 0.000 claims 1
- FMCYGTVHKAOLAM-UHFFFAOYSA-N 5-[1-[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]ethyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(C(C)C=2C=C3N(C)C(=O)OC3=CC=2)CC1 FMCYGTVHKAOLAM-UHFFFAOYSA-N 0.000 claims 1
- JGGYDCZSDBBBRD-UHFFFAOYSA-N 5-[2-[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]propan-2-yl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(C(C)(C)C=2C=C3N(C)C(=O)OC3=CC=2)CC1 JGGYDCZSDBBBRD-UHFFFAOYSA-N 0.000 claims 1
- WURIWQGPKUGNDP-UHFFFAOYSA-N 5-[[3-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-3-(methoxymethyl)pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)OC3=CC=2)CC1 WURIWQGPKUGNDP-UHFFFAOYSA-N 0.000 claims 1
- XZOXQUIEYCYENT-UHFFFAOYSA-N 5-[[3-(cyclopropylmethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzothiazol-2-one Chemical compound C=1C=C2SC(=O)N(C)C2=CC=1CN(C1)CCC1(C(=O)N1CC2=CC(=CN=C2CC1)C(F)(F)F)CC1CC1 XZOXQUIEYCYENT-UHFFFAOYSA-N 0.000 claims 1
- XQYUYQDUPFWDFK-UHFFFAOYSA-N 5-[[3-(cyclopropylmethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C=1C=C2OC(=O)N(C)C2=CC=1CN(C1)CCC1(C(=O)N1CC2=CC(=CN=C2CC1)C(F)(F)F)CC1CC1 XQYUYQDUPFWDFK-UHFFFAOYSA-N 0.000 claims 1
- QZGNXUYSPSJETI-UHFFFAOYSA-N 5-[[3-(cyclopropylmethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3h-1,3-benzothiazol-2-one Chemical compound C1C2=CC(C(F)(F)F)=CN=C2CCN1C(=O)C1(CN(CC=2C=C3NC(=O)SC3=CC=2)CC1)CC1CC1 QZGNXUYSPSJETI-UHFFFAOYSA-N 0.000 claims 1
- BBCOGOZIEGWDSI-UHFFFAOYSA-N 5-[[3-(ethoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COCC)CN(CC=2C=C3N(C)C(=O)OC3=CC=2)CC1 BBCOGOZIEGWDSI-UHFFFAOYSA-N 0.000 claims 1
- MUYBWGUUSUXSGK-UHFFFAOYSA-N 5-[[3-(hydroxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C(CO)(C1)CCN1CC1=CC=C(OC(N2C)=O)C2=C1 MUYBWGUUSUXSGK-UHFFFAOYSA-N 0.000 claims 1
- GMBBPAFILXICGE-UHFFFAOYSA-N 5-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-5,7-dihydropyrrolo[3,4-b]pyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1C2=CC(C(F)(F)F)=CN=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)OC3=CC=2)CC1 GMBBPAFILXICGE-UHFFFAOYSA-N 0.000 claims 1
- HZOYWQOTYROKEB-UHFFFAOYSA-N 5-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1,3-dimethylbenzimidazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)N(C)C3=CC=2)CC1 HZOYWQOTYROKEB-UHFFFAOYSA-N 0.000 claims 1
- FTRAKWZYZZKAGK-UHFFFAOYSA-N 5-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzothiazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)SC3=CC=2)CC1 FTRAKWZYZZKAGK-UHFFFAOYSA-N 0.000 claims 1
- JKEOMFGBWCCTCB-UHFFFAOYSA-N 5-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)OC3=CC=2)CC1 JKEOMFGBWCCTCB-UHFFFAOYSA-N 0.000 claims 1
- HSMJAYLNJMUKPQ-UHFFFAOYSA-N 5-bromo-6-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C(=CC=3N(C)C(=O)OC=3C=2)Br)CC1 HSMJAYLNJMUKPQ-UHFFFAOYSA-N 0.000 claims 1
- HYMXRSJFWFORFH-UHFFFAOYSA-N 6-[1-[3-(ethoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]ethyl]-4-methyl-1,4-benzoxazin-3-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COCC)CN(C(C)C=2C=C3N(C)C(=O)COC3=CC=2)CC1 HYMXRSJFWFORFH-UHFFFAOYSA-N 0.000 claims 1
- PUEDSWKAOHTFDD-UHFFFAOYSA-N 6-[1-[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]ethyl]-1-methyl-3h-indol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(C(C)C=2C=C3N(C)C(=O)CC3=CC=2)CC1 PUEDSWKAOHTFDD-UHFFFAOYSA-N 0.000 claims 1
- LGAFJIJPKCFJMJ-UHFFFAOYSA-N 6-[1-[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]ethyl]-4-methyl-1,4-benzoxazin-3-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(C(C)C=2C=C3N(C)C(=O)COC3=CC=2)CC1 LGAFJIJPKCFJMJ-UHFFFAOYSA-N 0.000 claims 1
- KDMYWUDMXFRDAA-UHFFFAOYSA-N 6-[3-(methoxymethyl)-1-[(3-methyl-2-oxo-1,3-benzoxazol-5-yl)methyl]pyrrolidine-3-carbonyl]-7,8-dihydro-5h-1,6-naphthyridine-3-carbonitrile Chemical compound C1CC2=NC=C(C#N)C=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)OC3=CC=2)CC1 KDMYWUDMXFRDAA-UHFFFAOYSA-N 0.000 claims 1
- XBICIUXGZNQOOH-UHFFFAOYSA-N 6-[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]-1-methyl-7,8-dihydro-6h-cyclopenta[e][1,3]benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(C2C3=C(C=4N(C)C(=O)OC=4C=C3)CC2)CC1 XBICIUXGZNQOOH-UHFFFAOYSA-N 0.000 claims 1
- MQRYXWFYGALVHE-XMMPIXPASA-N 6-[[(3r)-3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)[C@@]1(COC)CN(CC=2C=C3OC(=O)N(C)C3=CC=2)CC1 MQRYXWFYGALVHE-XMMPIXPASA-N 0.000 claims 1
- MQRYXWFYGALVHE-DEOSSOPVSA-N 6-[[(3s)-3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)[C@]1(COC)CN(CC=2C=C3OC(=O)N(C)C3=CC=2)CC1 MQRYXWFYGALVHE-DEOSSOPVSA-N 0.000 claims 1
- OQDPSJOSZREQPJ-UHFFFAOYSA-N 6-[[3-(cyclobutylmethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methylquinolin-2-one Chemical compound C1=C2C=CC(=O)N(C)C2=CC=C1CN(C1)CCC1(C(=O)N1CC2=CC(=CN=C2CC1)C(F)(F)F)CC1CCC1 OQDPSJOSZREQPJ-UHFFFAOYSA-N 0.000 claims 1
- PIQVXZKFAQSKCR-UHFFFAOYSA-N 6-[[3-(cyclopropylmethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methylquinolin-2-one Chemical compound C1=C2C=CC(=O)N(C)C2=CC=C1CN(C1)CCC1(C(=O)N1CC2=CC(=CN=C2CC1)C(F)(F)F)CC1CC1 PIQVXZKFAQSKCR-UHFFFAOYSA-N 0.000 claims 1
- FADIXOKHZVMUMM-UHFFFAOYSA-N 6-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methyl-3h-indol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)CC3=CC=2)CC1 FADIXOKHZVMUMM-UHFFFAOYSA-N 0.000 claims 1
- FISBGIQSOYEZGM-UHFFFAOYSA-N 6-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3,5-dimethyl-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C(=CC=3N(C)C(=O)OC=3C=2)C)CC1 FISBGIQSOYEZGM-UHFFFAOYSA-N 0.000 claims 1
- OJWKSQPOCNEAPC-UHFFFAOYSA-N 6-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-4-methyl-1,4-benzoxazin-3-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)COC3=CC=2)CC1 OJWKSQPOCNEAPC-UHFFFAOYSA-N 0.000 claims 1
- RFELKOVAJJRWQW-UHFFFAOYSA-N 6-[[3-benzyl-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methylquinolin-2-one Chemical compound C1=C2C=CC(=O)N(C)C2=CC=C1CN(C1)CCC1(C(=O)N1CC2=CC(=CN=C2CC1)C(F)(F)F)CC1=CC=CC=C1 RFELKOVAJJRWQW-UHFFFAOYSA-N 0.000 claims 1
- KAHPAFVECYYWPH-UHFFFAOYSA-N 6-chloro-5-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-3-methyl-1,3-benzoxazol-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C(=CC=3OC(=O)N(C)C=3C=2)Cl)CC1 KAHPAFVECYYWPH-UHFFFAOYSA-N 0.000 claims 1
- QAYVYYSKSWMXHC-UHFFFAOYSA-N 6-chloro-7-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methylquinolin-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C(=CC=3C=CC(=O)N(C)C=3C=2)Cl)CC1 QAYVYYSKSWMXHC-UHFFFAOYSA-N 0.000 claims 1
- NQTKKLPVDZGIDL-UHFFFAOYSA-N 7-[1-[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]ethyl]-1-methylquinoxalin-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(C(C)C=2C=C3N(C)C(=O)C=NC3=CC=2)CC1 NQTKKLPVDZGIDL-UHFFFAOYSA-N 0.000 claims 1
- DVJYNRLKAIQAGV-AREMUKBSSA-N 7-[[(3r)-3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methylquinolin-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)[C@@]1(COC)CN(CC=2C=C3N(C)C(=O)C=CC3=CC=2)CC1 DVJYNRLKAIQAGV-AREMUKBSSA-N 0.000 claims 1
- VUVWEEIPHLEDKR-MUUNZHRXSA-N 7-[[(3s)-3-(cyclopropylmethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methylquinolin-2-one Chemical compound C([C@@]1(CCN(C1)CC=1C=C2N(C(C=CC2=CC=1)=O)C)C(=O)N1CC2=CC(=CN=C2CC1)C(F)(F)F)C1CC1 VUVWEEIPHLEDKR-MUUNZHRXSA-N 0.000 claims 1
- DVJYNRLKAIQAGV-SANMLTNESA-N 7-[[(3s)-3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methylquinolin-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)[C@]1(COC)CN(CC=2C=C3N(C)C(=O)C=CC3=CC=2)CC1 DVJYNRLKAIQAGV-SANMLTNESA-N 0.000 claims 1
- VUVWEEIPHLEDKR-UHFFFAOYSA-N 7-[[3-(cyclopropylmethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methylquinolin-2-one Chemical compound C=1C=C2C=CC(=O)N(C)C2=CC=1CN(C1)CCC1(C(=O)N1CC2=CC(=CN=C2CC1)C(F)(F)F)CC1CC1 VUVWEEIPHLEDKR-UHFFFAOYSA-N 0.000 claims 1
- FVLARIBCAOKFPC-UHFFFAOYSA-N 7-[[3-(cyclopropylmethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1h-quinolin-2-one Chemical compound C1C2=CC(C(F)(F)F)=CN=C2CCN1C(=O)C1(CN(CC=2C=C3NC(=O)C=CC3=CC=2)CC1)CC1CC1 FVLARIBCAOKFPC-UHFFFAOYSA-N 0.000 claims 1
- DVJYNRLKAIQAGV-UHFFFAOYSA-N 7-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methylquinolin-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)C=CC3=CC=2)CC1 DVJYNRLKAIQAGV-UHFFFAOYSA-N 0.000 claims 1
- ICDLQSHCPNHELF-UHFFFAOYSA-N 7-[[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]methyl]-1-methylquinoxalin-2-one Chemical compound C1CC2=NC=C(C(F)(F)F)C=C2CN1C(=O)C1(COC)CN(CC=2C=C3N(C)C(=O)C=NC3=CC=2)CC1 ICDLQSHCPNHELF-UHFFFAOYSA-N 0.000 claims 1
- 229910014033 C-OH Inorganic materials 0.000 claims 1
- 229910014570 C—OH Inorganic materials 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241000157312 Rhinoderma Species 0.000 claims 1
- OOQHONFKITXICX-UHFFFAOYSA-N [1-[(4-hydroxy-3-methoxyphenyl)methyl]-4-(2-methylpropyl)piperidin-4-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1=C(O)C(OC)=CC(CN2CCC(CC(C)C)(CC2)C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)=C1 OOQHONFKITXICX-UHFFFAOYSA-N 0.000 claims 1
- LGKXVKJQRSAWHU-UHFFFAOYSA-N [1-[4-(4-fluorophenyl)cyclohexyl]-3-(methoxymethyl)pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1C(COC)(C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CCN1C(CC1)CCC1C1=CC=C(F)C=C1 LGKXVKJQRSAWHU-UHFFFAOYSA-N 0.000 claims 1
- DSVKFQLIERXNHL-UHFFFAOYSA-N [1-[4-(5-fluoropyridin-2-yl)cyclohexyl]-3-(methoxymethyl)pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1C(COC)(C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CCN1C(CC1)CCC1C1=CC=C(F)C=N1 DSVKFQLIERXNHL-UHFFFAOYSA-N 0.000 claims 1
- NMPJMQVHGFJCHG-UHFFFAOYSA-N [1-[4-fluoro-4-(6-methoxypyridin-3-yl)cyclohexyl]-3-(methoxymethyl)pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1C(COC)(C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CCN1C(CC1)CCC1(F)C1=CC=C(OC)N=C1 NMPJMQVHGFJCHG-UHFFFAOYSA-N 0.000 claims 1
- KSGFGNPWKSGEIX-UHFFFAOYSA-N [1-[4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl]-3-(methoxymethyl)pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1C(COC)(C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CCN1C(CC1)CCC1(O)C1=CC=C(OC)N=C1 KSGFGNPWKSGEIX-UHFFFAOYSA-N 0.000 claims 1
- XUAUUMXAZGNEDU-UHFFFAOYSA-N [3-(cyclopropylmethyl)-1-(1h-indazol-5-ylmethyl)pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1C2=CC(C(F)(F)F)=CN=C2CCN1C(=O)C1(CN(CC=2C=C3C=NNC3=CC=2)CC1)CC1CC1 XUAUUMXAZGNEDU-UHFFFAOYSA-N 0.000 claims 1
- WCUDZOJOQRBGIP-UHFFFAOYSA-N [3-(cyclopropylmethyl)-1-(oxan-4-ylmethyl)pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1C2=CC(C(F)(F)F)=CN=C2CCN1C(=O)C1(CN(CC2CCOCC2)CC1)CC1CC1 WCUDZOJOQRBGIP-UHFFFAOYSA-N 0.000 claims 1
- ISTJMLJJSJJKIJ-UHFFFAOYSA-N [3-(cyclopropylmethyl)-1-[(2,2-dimethyloxan-4-yl)methyl]pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1COC(C)(C)CC1CN1CC(CC2CC2)(C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CC1 ISTJMLJJSJJKIJ-UHFFFAOYSA-N 0.000 claims 1
- LEHJXILMAZFEBK-UHFFFAOYSA-N [3-(cyclopropylmethyl)-1-[(3-fluoro-4-hydroxyphenyl)methyl]pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1=C(F)C(O)=CC=C1CN1CC(CC2CC2)(C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CC1 LEHJXILMAZFEBK-UHFFFAOYSA-N 0.000 claims 1
- OYALIWAZSPYDLP-UHFFFAOYSA-N [3-(cyclopropylmethyl)-1-[(4-hydroxy-3-methoxyphenyl)methyl]pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1=C(O)C(OC)=CC(CN2CC(CC3CC3)(CC2)C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)=C1 OYALIWAZSPYDLP-UHFFFAOYSA-N 0.000 claims 1
- CIAUEEMOFGNWIP-UHFFFAOYSA-N [3-(cyclopropylmethyl)-1-[(5-methoxy-2-methyl-2,3-dihydro-1-benzofuran-6-yl)methyl]pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound COC1=CC=2CC(C)OC=2C=C1CN(C1)CCC1(C(=O)N1CC2=CC(=CN=C2CC1)C(F)(F)F)CC1CC1 CIAUEEMOFGNWIP-UHFFFAOYSA-N 0.000 claims 1
- VPGDDKHSBNUUEU-UHFFFAOYSA-N [3-(cyclopropylmethyl)-1-[4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl]pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1=NC(OC)=CC=C1C1(O)CCC(N2CC(CC3CC3)(CC2)C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CC1 VPGDDKHSBNUUEU-UHFFFAOYSA-N 0.000 claims 1
- DOGZDSFPEVVTTB-UHFFFAOYSA-N [3-(methoxymethyl)-1-(4-pyrimidin-2-ylcyclohexyl)pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1C(COC)(C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CCN1C(CC1)CCC1C1=NC=CC=N1 DOGZDSFPEVVTTB-UHFFFAOYSA-N 0.000 claims 1
- LJJFNVXBPXYBDE-UHFFFAOYSA-N [3-(methoxymethyl)-1-(4-pyrimidin-5-ylcyclohexyl)pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1C(COC)(C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CCN1C(CC1)CCC1C1=CN=CN=C1 LJJFNVXBPXYBDE-UHFFFAOYSA-N 0.000 claims 1
- SMGCPEBUGLUKSJ-UHFFFAOYSA-N [3-(methoxymethyl)-1-[4-(6-methoxypyridin-3-yl)cyclohexyl]pyrrolidin-3-yl]-[3-(trifluoromethyl)-7,8-dihydro-5h-1,6-naphthyridin-6-yl]methanone Chemical compound C1C(COC)(C(=O)N2CC3=CC(=CN=C3CC2)C(F)(F)F)CCN1C(CC1)CCC1C1=CC=C(OC)N=C1 SMGCPEBUGLUKSJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002723 alicyclic group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 0 CC(C)(CN=*)NC Chemical compound CC(C)(CN=*)NC 0.000 description 4
- UWYZHKAOTLEWKK-UHFFFAOYSA-N C(CNC1)c2c1cccc2 Chemical compound C(CNC1)c2c1cccc2 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- GYQAXMJLFPXZAU-UHFFFAOYSA-N O=C1NCCc2c1cccn2 Chemical compound O=C1NCCc2c1cccn2 GYQAXMJLFPXZAU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1281907P | 2007-12-11 | 2007-12-11 | |
| US61/012,819 | 2007-12-11 | ||
| US3667508P | 2008-03-14 | 2008-03-14 | |
| US61/036,675 | 2008-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010128543A true RU2010128543A (ru) | 2012-01-20 |
Family
ID=40352365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010128543/04A RU2010128543A (ru) | 2007-12-11 | 2008-12-11 | Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8569282B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2280766A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011506466A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100102646A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101925383A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008335135A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0820701A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2708364A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2010128543A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009076512A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2677291C2 (ru) * | 2012-05-31 | 2019-01-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соединения тетрагидропиразолопиримидина |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2685266C (en) | 2007-04-27 | 2014-01-28 | Purdue Pharma L.P. | Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal |
| BRPI0820701A2 (pt) | 2007-12-11 | 2015-06-16 | Cytopathfinder Inc | Composto de carboxamida e seu uso como agonistas do receptor de quimiocina |
| TW201105649A (en) * | 2009-04-16 | 2011-02-16 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 |
| EP2419419B1 (en) * | 2009-04-17 | 2014-12-03 | Janssen Pharmaceutica NV | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
| CN102459226B (zh) * | 2009-04-17 | 2014-09-17 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂 |
| PE20141531A1 (es) | 2011-06-22 | 2014-10-23 | Purdue Pharma Lp | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos |
| GB201115633D0 (en) * | 2011-09-09 | 2011-10-26 | Univ Liverpool | Compositions of efavirenz |
| KR102867210B1 (ko) * | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AU2023259236B2 (en) | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| WO2025055965A1 (zh) * | 2023-09-13 | 2025-03-20 | 中国药科大学 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
| WO2025131049A1 (en) * | 2023-12-21 | 2025-06-26 | Ignis Therapeutics (Suzhou) Limited | Dihydro-pyrrolo-pyridine derivatives and uses thereof |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB860303A (en) | 1958-06-20 | 1961-02-01 | Ici Ltd | Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª |
| US3383281A (en) | 1961-09-22 | 1968-05-14 | Merck & Co Inc | Method for binding bile acids in vivo |
| SE353319B (cg-RX-API-DMAC7.html) | 1964-08-15 | 1973-01-29 | Sumitomo Chemical Co | |
| US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
| US4058552A (en) | 1969-01-31 | 1977-11-15 | Orchimed Sa | Esters of p-carbonylphenoxy-isobutyric acids |
| US3803237A (en) | 1969-11-03 | 1974-04-09 | Upjohn Co | Reaction products of polyethylenepolyamines and chlorohydrins or epoxy containing compounds |
| US3692895A (en) | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
| DE2230383C3 (de) | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben |
| DE2708913A1 (de) | 1976-03-04 | 1977-09-08 | Hoechst Ag | Benzoylpiperidyalkyl-indole und verwandte verbindungen |
| FR2350341A1 (fr) | 1976-05-07 | 1977-12-02 | Synthelabo | Nouveaux derives de piperidine et leur methode de preparation |
| GB2021108B (en) | 1978-05-18 | 1982-07-21 | Pfizer Ltd | 6,7 - di - 4 - amino - 2 - quinazolines |
| DK159079A (da) | 1978-05-18 | 1979-11-19 | Pfizer | Fremgangsmaade til fremstilling af derivater af 4-amino-2-piperidinoquinazolin eller syreadditionssalte deraf |
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| US4452813A (en) | 1981-05-22 | 1984-06-05 | Taiho Pharmaceutical Company Limited | Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| US4847271A (en) | 1986-01-27 | 1989-07-11 | Merck & Co., Inc. | Antihypercholesterolemic β-lactones |
| US5041432A (en) | 1987-01-30 | 1991-08-20 | E. I. Du Pont De Nemours And Company | Steroid derivatives useful as hypocholesterolemics |
| US4716175A (en) | 1987-02-24 | 1987-12-29 | Warner-Lambert Company | Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase |
| US5015644A (en) | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
| EP0306375A1 (fr) | 1987-08-07 | 1989-03-08 | Synthelabo | Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique |
| WO1990005132A1 (fr) | 1988-11-11 | 1990-05-17 | Banyu Pharmaceutical Co., Ltd. | Derives d'allylamine substitues, procede de preparation et utilisation |
| US5064856A (en) | 1989-07-31 | 1991-11-12 | Merck & Co., Inc. | Novel hmg-coa synthase inhibitors |
| US5391571A (en) | 1989-11-15 | 1995-02-21 | American Home Products Corporation | Cholesterol ester hydrolase inhibitors |
| SE8904298D0 (sv) | 1989-12-21 | 1989-12-21 | Astra Ab | New compounds |
| US5102915A (en) | 1990-03-22 | 1992-04-07 | Merrell Dow Pharmaceuticals Inc. | Cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis |
| US5051534A (en) | 1990-03-22 | 1991-09-24 | Merrell Dow Pharmaceuticals Inc. | Novel cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis |
| US5011859A (en) | 1990-03-30 | 1991-04-30 | Merrell Dow Pharmaceuticals Inc. | Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase |
| US5064864A (en) | 1990-03-30 | 1991-11-12 | Merrell Dow Pharmaceuticals Inc. | Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase |
| US5120729A (en) | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
| ZA915659B (en) | 1990-07-25 | 1992-05-27 | Merrell Dow Pharma | Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis |
| US5026554A (en) | 1990-09-13 | 1991-06-25 | Merck & Co., Inc. | Method of inhibiting fungal growth using squalene synthetase inhibitors |
| US5084461A (en) | 1991-03-27 | 1992-01-28 | Merrell Dow Pharmaceuticals Inc. | Azadecalin amides and thioamides as inhibitors of cholesterol biosynthesis |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| WO1993011782A1 (en) | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
| CA2098167C (en) | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
| FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| US5364867A (en) | 1992-11-30 | 1994-11-15 | Sterling Winthrop Inc. | 4-phenylpiperdine agents for treating cns disorders |
| US5635510A (en) | 1993-05-06 | 1997-06-03 | Merrell Pharmaceuticals Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines |
| US5824690A (en) | 1993-05-06 | 1998-10-20 | Hoechst Marion Roussel Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines |
| TW381025B (en) | 1993-08-05 | 2000-02-01 | Hoffmann La Roche | Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor |
| SE9400447D0 (sv) | 1994-02-11 | 1994-02-11 | Astra Ab | New compounds |
| US5576313A (en) | 1994-08-29 | 1996-11-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| MX9703518A (es) | 1994-11-16 | 1997-08-30 | Synaptic Pharma Corp | Dihidropirimidinas y usos de las mismas. |
| US6268369B1 (en) | 1994-11-16 | 2001-07-31 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
| US5510379A (en) | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
| US5688960A (en) | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
| US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| DK0832069T3 (da) | 1995-06-07 | 2003-04-22 | Pfizer | Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) |
| FR2735129B1 (fr) | 1995-06-07 | 1997-07-11 | Adir | Nouveaux derives de l'indole, de l'indazole et du benzisoxazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6228861B1 (en) | 1995-11-16 | 2001-05-08 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
| US6245773B1 (en) | 1996-05-16 | 2001-06-12 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
| EA001539B1 (ru) | 1996-11-27 | 2001-04-23 | Пфайзер Инк. | Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр) |
| US5977139A (en) | 1996-12-15 | 1999-11-02 | Hoechst Marion Roussel, Inc. | Carboxysubstituted cyclic carboxamide derivatives |
| US5861417A (en) | 1996-12-19 | 1999-01-19 | Hoechst Marion Roussel, Inc. | Heterocyclic substituted pyrrolidine amide derivatives |
| US6136827A (en) | 1997-07-25 | 2000-10-24 | Merck & Co., Inc. | Cyclic amine modulations of chemokine receptor activity |
| JP2001513369A (ja) | 1997-08-11 | 2001-09-04 | アラーガン・セイルズ・インコーポレイテッド | 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法 |
| US6020347A (en) | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6316445B1 (en) | 1998-05-15 | 2001-11-13 | Aventis Pharmaceuticals Inc. | Carboxy substituted acylic carboxamide derivatives |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6133291A (en) | 1998-10-16 | 2000-10-17 | Schering Corporation | N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists |
| DE60009287T2 (de) | 1999-06-03 | 2005-02-17 | Yamanouchi Pharmaceutical Co., Ltd. | Neuartige isoquinolin-derivate oder salze davon |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| ATE250604T1 (de) | 1999-10-27 | 2003-10-15 | Millennium Pharm Inc | Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation |
| US6258833B1 (en) | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| JP2004506687A (ja) | 2000-08-23 | 2004-03-04 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| US6620438B2 (en) | 2001-03-08 | 2003-09-16 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists |
| US20020137764A1 (en) | 2000-10-31 | 2002-09-26 | Karin Drechsel | Inhalable formulation of a solution containing a tiotropium salt |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| US6608054B2 (en) | 2001-03-20 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and endothelin antagonists |
| EP1339438B1 (en) | 2000-11-29 | 2005-10-19 | Allergan Inc. | Preventing transplant rejection in the eye |
| MXPA03008356A (es) | 2001-03-13 | 2003-12-11 | Schering Corp | Compuestos del tipo no imidazol como antagonistas de histamina h3. |
| GB0118238D0 (en) | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
| BR0213611A (pt) | 2001-10-02 | 2005-12-20 | Acadia Pharm Inc | Composto, composição farmacêutica, seus usos, método para aumentar a atividade de um receptor colinérgico, métodos para tratamento ou prevenção de distúrbio mental, dor, pressão intraocular aumentada e progressão ou formação de placas amilóides |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| US7220735B2 (en) | 2002-04-18 | 2007-05-22 | Schering Corporation | Benzimidazolone histamine H3 antagonists |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US7230008B2 (en) | 2002-04-29 | 2007-06-12 | Merck & Co, Inc. | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| WO2004014377A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
| WO2004024720A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
| WO2004033427A1 (en) | 2002-10-11 | 2004-04-22 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
| PL1633724T3 (pl) * | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| CN1826334A (zh) * | 2003-03-18 | 2006-08-30 | 麦克公司 | 趋化因子受体活性的四氢吡喃基环戊基杂环酰胺调节剂 |
| EP1468999A1 (en) | 2003-03-20 | 2004-10-20 | MyoContract Ltd. | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| CN1764458A (zh) | 2003-03-26 | 2006-04-26 | 麦克公司 | 作为黑皮质素－4受体激动剂的双环哌啶衍生物 |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US20040259887A1 (en) | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| AU2004275488A1 (en) | 2003-09-26 | 2005-04-07 | Actelion Pharmaceuticals Ltd | Pyridine derivatives and use thereof as urotensin II antagonists |
| GB0325745D0 (en) | 2003-11-05 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
| JP2007522219A (ja) * | 2004-02-12 | 2007-08-09 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性のアミノ複素環式調節物質 |
| BRPI0509660A (pt) | 2004-04-09 | 2007-10-09 | Millennium Pharm Inc | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias |
| US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20070059336A1 (en) | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| CA2565599C (en) | 2004-05-18 | 2012-07-31 | Schering Corporation | Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors |
| US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2005121090A1 (en) | 2004-06-02 | 2005-12-22 | Abbott Laboratories | Substituted piperidines that have antiangiogenic activity |
| EP1778646A1 (en) | 2004-08-11 | 2007-05-02 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
| CN101065374A (zh) | 2004-09-28 | 2007-10-31 | 詹森药业有限公司 | 取代的二哌啶化学引诱物细胞因子受体2拮抗剂 |
| EP1802623A1 (en) | 2004-10-12 | 2007-07-04 | Novo Nordisk A/S | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds |
| FR2876692B1 (fr) * | 2004-10-19 | 2007-02-23 | Sanofi Aventis Sa | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique |
| MX2007006214A (es) | 2004-11-24 | 2008-04-16 | Therakine Ltd | Un implante para suministro de farmaco intraocular. |
| ES2434467T3 (es) | 2005-05-13 | 2013-12-16 | Lexicon Pharmaceuticals, Inc. | Compuestos multicíclicos y métodos para su uso |
| US7425633B2 (en) * | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
| WO2007053499A2 (en) * | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| AR063275A1 (es) | 2006-10-12 | 2009-01-14 | Epix Delaware Inc | Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2. |
| US20100184749A1 (en) | 2006-10-12 | 2010-07-22 | EPIX Delaware ,Inc. | Benzothiadiazine compounds and their use |
| WO2009076404A1 (en) | 2007-12-10 | 2009-06-18 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
| BRPI0820701A2 (pt) | 2007-12-11 | 2015-06-16 | Cytopathfinder Inc | Composto de carboxamida e seu uso como agonistas do receptor de quimiocina |
| WO2010129843A1 (en) | 2009-05-08 | 2010-11-11 | Cytopathfinder, Inc. | Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders |
-
2008
- 2008-12-11 BR BRPI0820701-1A patent/BRPI0820701A2/pt not_active IP Right Cessation
- 2008-12-11 US US12/747,109 patent/US8569282B2/en not_active Expired - Fee Related
- 2008-12-11 CN CN2008801255852A patent/CN101925383A/zh active Pending
- 2008-12-11 KR KR1020107015232A patent/KR20100102646A/ko not_active Ceased
- 2008-12-11 RU RU2010128543/04A patent/RU2010128543A/ru not_active Application Discontinuation
- 2008-12-11 WO PCT/US2008/086388 patent/WO2009076512A1/en not_active Ceased
- 2008-12-11 AU AU2008335135A patent/AU2008335135A1/en not_active Abandoned
- 2008-12-11 CA CA2708364A patent/CA2708364A1/en not_active Abandoned
- 2008-12-11 JP JP2010538152A patent/JP2011506466A/ja active Pending
- 2008-12-11 EP EP08858495A patent/EP2280766A1/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2677291C2 (ru) * | 2012-05-31 | 2019-01-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соединения тетрагидропиразолопиримидина |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008335135A1 (en) | 2009-06-18 |
| US8569282B2 (en) | 2013-10-29 |
| WO2009076512A1 (en) | 2009-06-18 |
| EP2280766A1 (en) | 2011-02-09 |
| JP2011506466A (ja) | 2011-03-03 |
| CN101925383A (zh) | 2010-12-22 |
| US20100324035A1 (en) | 2010-12-23 |
| CA2708364A1 (en) | 2009-06-18 |
| BRPI0820701A2 (pt) | 2015-06-16 |
| KR20100102646A (ko) | 2010-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010128543A (ru) | Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов | |
| JP2011506466A5 (cg-RX-API-DMAC7.html) | ||
| RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
| JP2019536768A5 (cg-RX-API-DMAC7.html) | ||
| JP2009538896A5 (cg-RX-API-DMAC7.html) | ||
| RU2012139830A (ru) | Производные пиразолопиперидина в качестве ингибиторов nadph - оксидазы | |
| RU2008125068A (ru) | Спироциклические соединения | |
| RU2020112759A (ru) | Гетероциклические соединения в качестве ингибиторов PAD | |
| RU2013132758A (ru) | ЗАМЕЩЕННЫЕ N-(1H-ИНДАЗОЛ-4-ИЛ) ИМИДАЗОЛ [1,2-a]ПИРИДИН-3- КАРБОКСАМИДНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ РЕЦЕПТОРНОЙ ТИРОЗИНКИНАЗЫ III ТИПА | |
| ES2902365T3 (es) | Compuestos de furanopirimidina sustituidos como inhibidores de PDE1 | |
| EA025520B1 (ru) | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| JP2011500774A5 (cg-RX-API-DMAC7.html) | ||
| HUE028773T2 (en) | Substituted 2,3-dihydroimidazole [1,2-c] quinazoline derivatives for the treatment of hyper-proliferative disorders and diseases associated with angiogenesis | |
| WO2018218133A1 (en) | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors | |
| JP2013508404A5 (cg-RX-API-DMAC7.html) | ||
| RU2007128625A (ru) | Гетероциклические замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 | |
| JP6442485B2 (ja) | 新規二環性または三環性複素環化合物 | |
| JP2023520759A5 (cg-RX-API-DMAC7.html) | ||
| RU2008141761A (ru) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ | |
| JP2022502424A5 (cg-RX-API-DMAC7.html) | ||
| HRP20120105T1 (hr) | Aminoheterociklički spojevi | |
| JP2014518267A5 (cg-RX-API-DMAC7.html) | ||
| JP2016523911A5 (cg-RX-API-DMAC7.html) | ||
| JP2018514552A5 (cg-RX-API-DMAC7.html) | ||
| RU2012145237A (ru) | Производные арилэтинила |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140606 |